Arun Swaminath, MD

Director, Inflammatory Bowel Disease Program, Division of Gastroenterology Hepatology and Nutrition, Northwell Health

Associate Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Phone: (212) 434-6785

About the Investigator

Dr. Swaminath serves as the director of the Inflammatory Bowel Diseases Program at Lenox Hill Hospital. He is a practicing gastroenterologist with a clinical practice focused on treating patients with Crohn’s and colitis, a major contributor to the gastroenterology fellowship training program at Lenox Hill Hospital, and with an appointment as an Associate Professor in the School of Medicine at Hofstra University.

In addition to authoring numerous original clinical, translational, and review articles, Dr. Swaminath is a sought after speaker in the field of inflammatory bowel diseases. He has served as a NYC Crohn’s and Colitis Foundation Chapter Medical Advisory Committee chair and currently participates as a member of the national scientific advisory Professional Education Committee. He has been featured on television news, and numerous print and online media. He is a sought after speaker for Grand Rounds, patient societies, and teaching conferences.

Dr. Swaminath has a thriving multidisiplinary research program, involing both Phase III clinical trials to offer current edge biological therapy for patients with IBD unresponsive to standard therapy as well investigator initiated clinical projects in collaboration with the major medical centers in NYC.

Research Focus

Dr. Swaminath’s areas of interest include, diet in IBD, determining cause of death in IBD patients using the city and state department of health database, studying the best  treatments for IBD complicated by clostridium difficile, and management of iatrogenic injury in colitis patients. He has successfully served as a mentor to medical students, residents, MPH program graduates, and GI fellows with a strong track record of publication.


Mount Sinai School of Medicine
Degree: Fellowship
Field of Study: IBD Research

University of California, San Diego
Degree: Fellowship
Field of Study: Gastroenterology

University of California, San Diego
Degree: Residency
Field of Study: Chief Medical Resident

University of California, San Diego
Degree: Residency
Field of Study: Medicine

University of California, San Diego
Degree: MD

Lab Members

Laura Durbin, MPH
Senior Research Coordinator

Isabel Roitman, NP

Honors and Awards

2013 Mentor at AGA Investing in the Future-Clinical Research in IBD, DDW
2012 Co-Chair: NY CCFA Chapter Medical Advisory Committee (ongonig)
2011 Columbia Summer Research Institute: Comparative Effectiveness Research Scholarship
2010 Ellen Scherl International Scholar Award
2006 ASGE Workshop on Achieving Academic Success, Washington D.C.
2006 Crohn’s & Colitis Foundation of America: IBD Fellowship, Mt. Sinai, NY
2006 Collaborations in IBD: A fellows mentoring program. Chandler, AZ
2005 AGA 11th Annual Methodologies in Healthcare Outcomes in Gastroenterology

  1. Swaminath A, Feathers A, Ananthakirshnan A, Falzon L, Li Ferry S. “Systematic review with Meta-Analysis: Enteral Nutrition therapy for the Induction of Remission in Pediatric Crohn’s Disease.” Alimentary Pharmacology & Therapeutics. 2017, Aug 16
  2. Korelitz BI, Sonapal N, Schneider J, Swaminath A, Felder J, Roslin M, Aronoff J. “Obestity/Bariatry Surgery and Crohn’s disease.” J Clin Gastroenterol 2017 May 9.
  3. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. “The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn’s Disease: Results From the US VICTORY Consortium.” Am J Gastroenterol. 2016 Aug;111(8):1147-55. doi: 10.1038/ajg.2016.236.
  4. Feathers A, Yen T, Yun L, Strizich G, Swaminath A. “Internet Searches about Therapies Does Not Impact Willingness to Accept Prescribed Therapy in Inflammatory Bowel Disease Patients.” Dig Dis Sci. 2016 Apr;61(4):1013-20. doi: 10.1007/s10620-015-3981-5. Epub 2015 Dec 10
  5. Longman RA, Diehl G, Huh J, Swaminath, A, Miraldi E, Scherl E, Littman D.  “Microbiota Regulate CX3CR1+ Mononuclear Phagocytes to support Colitis-Associated Innate Lymphoid Cell Production of IL-22.” The Journal of Experimental Medicine 2014 Jul 28;211(8):1571-83.
  6. Swaminath A, Bhadelia N, Wang C.  “Cost-Effectiveness of QuantiFERON prior to initiation of biologic therapy in inflammatory bowel disease.” Inflammatory Bowel Disease Journal 2013, Aug 13.
  7. Lior Latz, Javier P Gisbert, Beth Manoogian, Kirk Lin, Casper Steenholdt, Gerassimos J Mantzaris, Ashish Atreja, Yulia Ron, Arun Swaminath, Somal Shah, Alisa Hart, Peter Laszlo Lakatos, Pierre Ellul, Eran Israeli, Mads Naundrup Svendsen, C. Janneke van der Woude, Konstantinos H. Katsanos, Laura Yun, Epameinondas V. Tsianos,  Torben Nathan, Maria Abreu, Iris Dotan, Bret Lashner, Jorn Brynskov, Jonathan P. Terdiman, Peter Higgins, Maria Chaparro, Shomron Ben-Horin. “Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response.” Inflammatory Bowel Disease Journal.  2012, Jan 31
  8. Ting-Chin David Shen,; Benjamin Lebwohl; Himanshu Verma; Nikhil Kumta; Christina Tennyson,; Suzanne Lewis, MD1; Ellen Scherl; Arun Swaminath; Kristina Capiak; Dan DiGiacomo; Brian P. Bosworth; Thomas H. Brannagan III; Peter H.R. Green. “Peripheral Neuropathic Symptoms in Celiac Disease and Inflammatory Bowel Disease.” Journal of Clinical Neuromuscular Disease.  2012, Mar 13(3):137-145
  9. Swaminath A, Lebwohl B, Capiak K, Present D. “Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn’s disease: A U.S. national practice survey comparing experts and non-experts.”  Digestive Diseases & Sciences. 2011 Apr 56(4):1160-64.
  10. Swaminath A, Longstreth G, Runnman E, Yang Su-Jau. “Effect of physician education and patient counseling on inpatient percutaneous feeding tube placement rate, indications, and outcome.” Southern Medical Journal. 2010, Feb 103(2):126-130.
  11. Swaminath A, Abreu M. “Early academic experience with the use of adalimumab in the treatment of Inflammatory bowel disease.” Alimentary Pharmacology & Therapeutics. 2009 Feb 1: 29(3):  273-8.
  12. Swaminath A, Lichtiger S. “Infliximab injection for the treatment of colonic strictures due to Crohn’s disease.”  Inflammatory Bowel Diseases. 2008 Feb;14(2):213-6.
  13. Kothari M, Mudireddy P, Swaminath A. “Patient Considerations in the management of ulcerative colitis – role of vedolizumab.” Therapeutics and Clinical Risk Management. 2015 Aug 19;11:1235-42
  14. Hudesman D, Mazurek J, Swaminath A. “Capsule Endoscopy in Crohn’s Disease: Are we seeing any better?” World Journal of Gastroenterology 2014 Sept 28; 20(36): 13044-13051.
  15. Swaminath A, Taunk R, Lawlor G. “Use of methotrexate in inflammatory bowel disease in 2014: A User’s guide.”  World Journal of Gastrointestinal Pharmacology & Therapeutics.  2014 Sept 6; 5(3):113-121.
  16. Krishnareddy S, Swaminath A. “When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease.” World Journal of Gastroenterology. 2014 Feb 7; 20(5):1139-1146
  17. Krishnareddy S, Swaminath A. “Update on the use of adalimumab in the management of Crohn’s disease.”  2013, Journal of Symptoms and Signs, Vol 2.
  18. Longman  R, Swaminath A. “Microbial manipulation as primary therapy for Crohn’s disease.” World Journal of Gastroenterology, 2013 March 14; 19(10): 1513-1516.
  19. Swaminath A, Present D. “Practical considerations in prescribing Anti-TNF therapy to your Crohn’s disease patients.” Visible Human Journal of Endoscopy.  2011 (10): Issue 1
  20. Swaminath A, Kornbluth A. “Use of video capsule endoscopy in Crohn’s disease.” Minerva gastroenterolgoica e dietologica.  2010 Dec; 56(4):437-49.
  21. Swaminath A, Kornbluth A. “Video capsule endoscopy in inflammatory bowel disease: Past, Present, & Future Redux.” Inflammatory Bowel Diseases.  2010 (7): 1254-1262
  22. Sharaiha R, Swaminath A. “A review of delayed release MMX-Mesalamine: It’s use in the treatment of ulcerative colitis.” Clinical Medicine: Therapeutics 2009 (1). 45-51
  23. Swaminath A, Kornbluth A. “Optimizing drug therapy in inflammatory bowel disease.” Current Gastroenterology Reports 2007, 9:513-520

View more at PubMed